RNAC Stock Price | Cartesian Therapeutics Inc. P/E, Revenue, EPS, & Forecasts

Cartesian Therapeutics Inc. • RNAC

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Cartesian Therapeutics Inc.

Ticker

RNAC

Trading on

NASDAQ

ISIN

US8162121045

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Carsten Brunn Ph.D.

Headquarters

704 Quince Orchard Road, Gaithersburg, MD, United States, 20878

Employees

Website

cartesiantherapeutics.com

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Metrics

BasicAdvanced

Market cap

$430M

P/E ratio

EPS

-$47.22

Dividend Yield

0.00%

Beta

0.83

Forward P/E ratio

25.45

EBIDTA

$-39.8M

Ex dividend date

Price & volume

Market cap

$430M

Average daily volume

0.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

25.45

PEG ratio

Trailing P/E

Price to sales

9.62

Price to book

613.03

Earnings

EPS

-$47.22

EPS estimate (current quarter)

-$1.07

EPS estimate (next quarter)

-$0.91

EBITDA

$-39.8M

Revenues (TTM)

$47.9M

Revenues per share (TTM)

$3.92

Technicals

Beta

0.83

52-week High

$41.87

52-week Low

$11.67

50-day moving average

$18.96

200-day moving average

$20.16

Short ratio

16.49

Short %

13.35%

Management effectiveness

ROE (TTM)

7,029.26%

ROA (TTM)

10.95%

Profit margin

0.00%

Gross profit margin

$38.4M

Operating margin

4,541.34%

Growth

Quarterly earnings growth (YoY)

53.70%

Quarterly revenue growth (YoY)

94.10%

Share stats

Outstanding Shares

23.9M

Float

9.6M

Insiders %

58.43%

Institutions %

22.47%

Analyst Insights & forecasts

75% Buy

25% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$43.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.06

Q3 • 23Beat

-$0.07

-$0.04

75.00%

Q4 • 23Beat

-$10.50

-$0.88

1,093.18%

Q1 • 24Beat

$0.54

-$1.07

150.47%

Q2 • 24Beat

-$1.13

-$0.79

43.04%

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$33.4M

$13.8M

41.37%

Q2 • 24

$0.4M

$-24.2M

6,248.84%

Q3 • 24

98.84%

274.78%

15,204.97%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$348M

$449M

129.18%

Q2 • 24

$455M

99.83%

Q3 • 24

30.94%

1.20%

22.71%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-14.4M

$-1.6M

$0.1M

$-16M

Q2 • 24

$13.7M

$-6.2M

$124M

$7.5M

Q3 • 24

194.77%

290.61%

103,645.00%

146.73%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cartesian Therapeutics Inc. share?

Cartesian Therapeutics Inc. shares are currently traded for undefined per share.

How many shares does Cartesian Therapeutics Inc. have?

Cartesian Therapeutics Inc. currently has 23.9M shares.

Does Cartesian Therapeutics Inc. pay dividends?

No, Cartesian Therapeutics Inc. doesn't pay dividends.

What is Cartesian Therapeutics Inc. 52 week high?

Cartesian Therapeutics Inc. 52 week high is $41.87.

What is Cartesian Therapeutics Inc. 52 week low?

Cartesian Therapeutics Inc. 52 week low is $11.67.

What is the 200-day moving average of Cartesian Therapeutics Inc.?

Cartesian Therapeutics Inc. 200-day moving average is $20.16.

Who is Cartesian Therapeutics Inc. CEO?

The CEO of Cartesian Therapeutics Inc. is Dr. Carsten Brunn Ph.D..

How many employees Cartesian Therapeutics Inc. has?

Cartesian Therapeutics Inc. has 37 employees.

What is the market cap of Cartesian Therapeutics Inc.?

The market cap of Cartesian Therapeutics Inc. is $430M.

What is the P/E of Cartesian Therapeutics Inc.?

The current P/E of Cartesian Therapeutics Inc. is null.

What is the EPS of Cartesian Therapeutics Inc.?

The EPS of Cartesian Therapeutics Inc. is -$47.22.

What is the PEG Ratio of Cartesian Therapeutics Inc.?

The PEG Ratio of Cartesian Therapeutics Inc. is 0.

What do analysts say about Cartesian Therapeutics Inc.?

According to the analysts Cartesian Therapeutics Inc. is considered a buy.